Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

The Efficacy and Safety of Basal Insulin – GLP-1 RA combination therapy

About the accreditation

EFFICACY AND SAFETY PROFILE OF BASAL INSULIN – GLP1-RECEPTOR AGONIST COMBINATION THERAPIES

HARDWARE AND SOFTWARE

 

The Insuline Educational Programme courses, which have been developed using HTML5 technologies, are accessible by using the following browsers:

Laptop/Desktop Version

IE9.0

IE10

IE11

Chrome
latest (version 48)

Safari latest

Firefox
latest

Win 7

Yes

Yes

Yes

Yes

Yes

Win 8.1

  

Yes

Yes

Yes

 -

Yes 

Mac 10.7x

 

 

 

-

Yes

 

Mac 10.8x

-

-

Yes

-

Certain activities may require additional software to view multimedia, presentations, or printable versions of the content. These activities will be marked as such and links will be provided to the required software. That software may include: Adobe Flash Player, Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

 

ACCREDITATION STATEMENT

“The Efficacy and Safety of Basal Insulin – GLP-1 RA combination therapy”, made available on “https://diabetes.elsevierresource.com/” and organized by “Elsevier”, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

“The Efficacy and Safety of Basal Insulin – GLP-1 RA combination therapy”, made available on “https://diabetes.elsevierresource.com/” and organized by “Elsevier”, is awarded “1” European CME credits (ECMEC's).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

DISCLOSURES AND CONFLICTS OF INTEREST
It is the policy of the UEMS-EACCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this e-CME activity discloses the following:
 

Faculty member and physician taking responsibility for content

 

Manufacturer

 

Relationship

Prof. Tina Vilsbøl

 

Novo Nordisk, Eli-Lilly

Amgen, AstraZeneca, Boehringer, BMS, Eli-Lilly, MSD, Novo Nordisk, Novartis, Takeda

Amgen, AstraZeneca, Boehringer, BMS, Eli-Lilly, MSD, Novo Nordisk, Novartis, Takeda

 

Grant/Research Support

 

Consultant

 

 

Speaker’s Bureau

Prof. Stephen Colagiuri

 

AstraZeneca, Janssen-Cilag, Merck Sharp & Dohme, Medtronics, Novartis, Novo Nordisk, Sanofi-aventis, Servier, and Takeda

AstraZeneca, Merck Sharp & Dohme, Novartis, Novo Nordisk, Servier, Sanofi-aventis, and Takeda

 

Consultant


 

Speaker’s Bureau

Prof. Bernard Zinman

 

Novo Nordisk

Novo Nordisk, Eli Lilly and Sanofi

 

Grand/Research Support

Consultant

Prof. Vivian Fonseca

 

Tulane

Asahi, Bayer, Endo Barrier, Gilead Sciences

Takeda, Novo Nordisk, Eli Lilly, Sanofi-aventis, AstraZeneca, Jansen, Intarcia

 

Research Support


Grants
 

Consultant

 

CONFLICT OF INTEREST STATEMENT

Elsevier has obtained the above signed faculty disclosures and has submitted these to the UEMS-EACCME to implement any process to resolve conflicts of interest for this CME activity. In order to help ensure that content of this course is objective, independent, fairly balanced, and aligned with the interest of the public.

 

UNAPPROVED/OFF-LABEL USE DISCLOSURE

The UEMS-EACCME requires CME faculty to disclose to the participants:

  • If products or procedures being discussed in a course are off-label, unlabeled, experimental, and/or investigational
  • Whether any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
  • That medical advisors, authors, speakers and/or moderators disclose when a product is not approved or not approved for the use under discussion.

 

 

INTENDED AUDIENCE

This activity has been developed for diabetes specialists. Due diligence and care have been taken when preparing module content to reflect the internationally recognized WHO, FDA, EMA terminologies. Furthermore, the module contents were drawn from a number of other countries worldwide, and the literature cited within the modules includes both European and global datasets, thus reflecting an international perspective on the topics. The content uses terminology fully consistent with the relevant peer-reviewed literature, and no country-specific brand names are used. It is therefore considered appropriate for an international audience.

 

PROGRAMME GOALS

Having completed this e-learning course and its accompanying self-assessment questions, the learner should have gained an increased understanding of:

  • The different insulin intensification therapies

  • The rationale for combining basal insulin with a GLP1-receptor agonist

  • The current published clinical trials evaluating the efficacy and safety outcomes of basal insulin – GLP-1 RA combination therapies

  • The improved safety profile of the basal insulin–GLP1-receptor agonist combination

  • The convenience of basal insulin–GLP1-receptor agonist combination

  • The management of patients for whom treatment with a basal insulin–GLP1-receptor agonist combination would be a viable option

 

EDUCATIONAL OBJECTIVES

The educational needs will be achieved by systemically addressing the need for communication through:

  • (a) Raising awareness of basal insulin–GLP-1 RA combination therapy, to support physicians in recognising the practical implications, such as efficacy, safety, and convenience.
  • (b) Assessing the competency of the learner through a post-test evaluation after completion of the course.
  • (c) Assessing the quality of the course by the learners through a post-course evaluation to be completed by the learner

CME CREDIT INFORMATION

Release Date: 23 December 2016
Expiration Date: 23 December 2018
Accreditation: 1 hour

 

FINANCIAL SUPPORT

Disclosure of Financial Relationships:
Elsevier hereby discloses that the e-Learning Modules and Resource Center is sponsored by Novo Nordisk.

Statement of Purpose:
The Activity is for scientific and educational purposes only and will not promote Novo Nordisk’s products, directly or indirectly and is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence, or provide favourable formulary status for any of it’s products. The website is based upon a budget proposal provided to Novo Nordisk by Elsevier reflecting a good faith estimate of the actual cost of the educational or scientific Activity to be funded pursuant to this Letter of Agreement. The amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novo Nordisk and Elsevier or any of their respective officers, directors, employees, agents, affiliates, parents, or subsidiaries.

Control of Content:
Elsevier is responsible for control of content and selection of medical advisors, authors, presenters, and moderators (if any). Novo Nordisk will not “script,” target points for emphasis or control in any way the planning, content, author/speaker selection, or execution of any Activity that is funded.

Objectivity & Balance:
The Activity will be independent, non-promotional, and free from commercial influence or bias. If Novo Nordisk’s products are mentioned in the course of this Activity, Elsevier will make every effort to ensure that data regarding Novo Nordisk’s products (and competing products) are objectively selected and presented, with favourable and unfavourable information and balanced discussion of prevailing information on the product(s) and/or alternate treatments. The title of the Activity will fairly and accurately represent the scope of the presentation. The Activity will present discussion of multiple treatment options, and will not focus on a single product, except when options are so limited as to preclude meaningful discussion. Elsevier will ensure, to the extent possible, disclosure of limitations of data, e.g. ongoing research, interim analyses, preliminary data, or unsupported opinion.

USER PRIVACY AND CONFIDENTIALITY STATEMENT
Elsevier, being the developer and provider of this activity, respects and confirms the privacy and confidentiality of the Learner, and confirms that any information provided by the Learner will only be utilized for the specific purposes of completing the material.

 

RELEVANT ETHICAL, MEDICO-LEGAL, AND LEGAL REQUIREMENTS

Elsevier agrees to abide by all relevant standards including: (a) the governing accrediting body standards; (b) Union of European Medical Specialist guidelines; (c) any locally relevant Pharmaceutical Code; and (f) all other obligations under applicable mandatory legislation.

The course will be provided to the Learner, subject to Elsevier’s online Privacy Policy and its online general Terms and Conditions.

The disclaimer below shall be included in the Terms and Conditions which specifically relates to medical or health services information:

“If the Content contained on this site contains medical or health sciences information, it is intended for professional use within the medical field. No suggested test or procedure should be carried out unless, in the reader's judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages should be made. Discussions, views, and recommendations as to medical procedures, products, choice of drugs, and drug dosages are the responsibility of the authors.”

 

HELP – ASSISTANCE

The course has a built in user help button to guide the learner through all relevant areas of the course.
 

CONTACT DETAILS FOR TECHNICAL OR OTHER ASSISTANCE

The Insulin Educational Programme have provided the email address of: elsevierpharmasolutions@elsevier.com

The learner/user may address all issues regarding the course and or website via this address which will be monitored 24 hours daily and responded to within 48–72 hours of the inquiry.

 

TO PRINT YOUR CERTIFICATE

The learner/user will be prompted and guided to the Insulin Programme modules for course evaluation feedback and a printable certificate.

 

DESCRIPTION OF PROVIDER

Elsevier is committed to making genuine contributions to the science and health communities. We are proud to be part of the science and health communities and to participate in the advancement of these fields. By delivering world-class information and innovative tools to researchers, students, educators, and practitioners worldwide, we help them become increasingly more productive in their work. We make substantial investments of capital and resources, which are required to manage the complex processes and innovations that serve the needs of the global science and health communities.

 

NAMES AND QUALIFICATIONS OF INDIVIDUALS RESPONSIBLE FOR PREPARATION OF CONTENT

 

Prof. Stephen Colagiuri, Professor of Metabolic Health Medicine and Director, The Boden Institute, University of Sydney, Sydney, Australia

Prof. Vivian A. Fonseca, MD, FRCP, Tulane Univ. Health Sciences Center, New Orleans, LA, USA

Prof. Tina Vilsbøll, MD, DMSc, Director of Center for Diabetes Research and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

Prof. Bernard Zinman, CM, MD, FRCPC, FACP, Director, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada

 

Disclosure
The physicians taking responsibility for the content and the medical advisor were responsible for the medical content and received editorial/writing support in the preparation of this course. This course has been sponsored by Novo Nordisk.


Acknowledgment
Giorgio Sesti, MD, Professor of Internal Medicine, independent reviewer, University Magna Graecia of Catanzaro, Catanzaro, Italy
Dr. Adriana Stan, PhD, CMPP, provided scientific writing/editing support for this course

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.


Search this site

Search form


 

Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk